<?xml version="1.0" encoding="UTF-8"?>
<p id="Par48">A candidate vaccine from Moderna named mRNA-1273 was registered by the National Institute of Allergy and Infectious Diseases (NIAID) in February 2020 to be tested in Seattle, Washington, with studies on human candidates being conducted beginning in March 2020 [
 <xref ref-type="bibr" rid="CR40">40</xref>].
</p>
